Early-stage collaborations between academia and industry are essential for driving innovation in the biotech industry but can come with inherent risk and potential legal, financial, or scientific challenges specific to each party. How to align industry and academia’s goals to make sure each party gets the most out of the collaboration? What are the common risks associated with early-stage academia-industry collaborations for both parties and how can they be identified and assessed from outset? What are the best practices in mitigating these risks and ensuring successful outcomes? How to manage intellectual property and confidentiality? How to measure the success of a collaboration?
Moderator: Gerald Law, Chief Executive, Innovation DB 
